U. Nubbemeyer et al.
FULL PAPER
NaHCO3 (2 ϫ) and brine (1 ϫ). The combined aqueous phases
were reextracted with diethyl ether (3ϫ). The combined organic
phases were dried (MgSO4) and concentrated under vacuum. The
crude azoninone 8–13 was purified by flash chromatography.
(C-4), 49.5 (C-10), 49.9 (C-9), 55.2 (C-3), 61.2 (C-20), 71.8 (C-8),
115.8 (C-23), 121.6 (C-25), 129.4 (C-6), 127.7 (C-14), 127.9 (C-18),
128.1 (C-12), 128.4 (C-13), 128.6 (C-17), 128.9 (C-24), 129.2 (C-
16), 132.2 (C-5), 137.2 (C-11), 137.7 (C-15), 157.0 (C-21), 171.0 (C-
19), 173.2 (C-2) ppm. IR: ν = 3029 (w), 2933 (w), 1729 (s), 1637
˜
(pS) E-3R,4S,8R-N-Benzyl-3-chloro-4-methoxycarbonyl-8-(phen-
oxy)-2,3,4,7,8,9-hexahydro-1H-azonin-2-one (pS-8c): Reaction be-
tween allylamine E-6c (0.11 g, 0.33 mmol) and chloroacetyl fluor-
ide (0.12 mL, 1.63 mmol) following standard procedure C. Purifica-
tion by column chromatography (PE/EtOAc, 6:1) gave pS-8c (64%)
as a yellow oil. Rf = 0.38 (PE/EtOAc, 4:1). 1H NMR (400 MHz,
CDCl3, amide conformation A): δ = 2.51 (dd, 2J = 11.4, 3J =
(s), 1597 (m), 1451 (m), 1225 (s), 1157 (s), 1033 (m), 942 (w), 752
(s), 695 cm–1. HRMS (ESI): calcd. for C30H31NO4Na [M + Na]+
492.2151; found 492.2163. [α]D = –115 (c = 1.03, CH2Cl2).
(pS) E-3S,4R,8S-N-Benzyl-3-chloro-4-ethoxycarbonyl-8-(phenoxy)-
2,3,4,7,8,9-hexahydro-1H-azonin-2-one (pS-20c) and (pS) E-
3R,4R,8S-N-Benzyl-4-ethoxycarbonyl-8-(phenoxy)-3-phenyl-
2,3,4,7,8,9-hexahydro-1H-azonin-2-one (pS-21c): Reaction between
allylamine Z-7c (4.0 g, 11.38 mmol) and chloroacetyl fluoride
(4.8 mL, 79.6 mmol) following standard procedure C. Purification
by column chromatography (PE/EtOAc, 8:1) gave pS-20c (68%) as
a pale yellow oil, and pS-21c (10%) as a pale yellow oil.
2
3
6.0 Hz, 1 H, 7a-H), 2.77 (dd, J = 13.5, J = 4.1 Hz, 1 H, 7b-H),
2
3
3.59 (dd, J = 15.4, J = 5.0 Hz, 1 H, 9a-H), 3.81 (s, 3 H, 20-H),
3
3
2
3.89 (dd, J = 9.5, J = 2.3 Hz, 1 H, 4-H), 4.50 (d, J = 15.4 Hz, 1
2
3
H, 10a-H), 4.69 (d, J = 15.4 Hz, 1 H, 9b-H), 4.88 (t, J = 5.3 Hz,
1 H, 8-H), 5.43 (d, J = 2.5 Hz, 1 H, 3-H), 5.46 (d, J = 15.6 Hz,
3
2
3
3
3
1
1 H, 10b-H), 5.99 (ddd, J = 15.8, J = 11.2, J = 4.2 Hz, 1 H, 6-
Data for pS-20c. Rf = 0.3 (PE/EtOAc, 5:1). H NMR (400 MHz,
H), 6.15 (dd, 3J = 16.0, 3J = 9.6 Hz, 1 H, 5-H), 6.90 (d, 3J = 7.9 Hz,
3
CDCl3): δ = 1.31 (t, J = 7.1 Hz, 3 H, 21-H), 2.31–2.42 (m, 1 H,
3
3
2
3
7-Hβ), 3.07 (dd, J = 13.2, J = 7.6 Hz, 1 H, 7-Hα), 3.57–3.62 (m,
2 H, 16-H), 7.01 (t, J = 7.4 Hz, 1 H, 18-H), 7.13 (d, J = 7.0 Hz,
2 H, 17-H), 7.28–7.35 (m, 5 H, 12-H, 13-H, 14-H); (amide confor-
mation B): 2.32–2.33 (m, 1 H, 7a-H), 2.47 (dd, 2J = 11.4, 3J =
6.2 Hz, 1 H, 7b-H), 3.38 (dd, J = 15.2, J = 4.1 Hz, 1 H, 9a-H),
3.79–3.80 (m, 1 H, 9b-H), 3.83–3.85 (m, 1 H, 4-H), 3.85 (s, 3 H,
20-H), 4.45 (d, 2J = 14.6 Hz, 1 H, 10a-H), 4.61–4.65 (m, 1 H, 8-
1 H, 4-H), 3.65 (d, J = 16.2 Hz, 1 H, 9-Hβ), 3.81–3.95 (m, 2 H, 9-
2
Hα), 4.20–4.33 (m, 2 H, 20-H), 4.38 (d, J = 14.2 Hz, 1 H, 10a-H),
2
2
3
3
4.63–4.70 (m, 1 H, 8-H), 5.14 (d, J = 9.8 Hz, 1 H, 3-H), 5.60 (dd,
2J = 14.2, J = 1.1 Hz, 1 H, 10b-H), 5.78–5.91 (m, 2 H, 5-H, 6-H),
4
3
3
6.92 (d, J = 7.8 Hz, 2 H, 16-H), 7.01 (t, J = 7.4 Hz, 1 H, 18-H),
7.21–7.27 (m, 5 H, 12-H, 13-H, 14-H), 7.28–7.34 (m, 2 H, 17-H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 14.2 (C-21), 36.2 (C-7), 48.8
(C-9), 49.7 (C-10), 50.4 (C-4), 57.0 (C-3), 61.9 (C-20), 74.4 (C-8),
115.8 (C-16), 122.0 (C-18), 127.6 (C-14), 128.6 (C-13), 129.0 (C-
12), 129.4 (C-5 or C-6), 129.9 (C-17), 130.2 (C-5 or C-6), 136.8 (C-
2
3
H), 4.94 (d, J = 15.1 Hz, 1 H, 10b-H), 5.08 (d, J = 7.9 Hz, 1 H,
3-H), 5.87–5.90 (m, 2 H, 5-H, 6-H), 6.76 (d, J = 7.9 Hz, 2 H, 16-
3
3
3
H), 6.99 (t, J = 7.1 Hz, 1 H, 18-H), 7.22 (d, J = 7.1 Hz, 2 H, 17-
H), 7.29–7.32 (m, 5 H, 12-H, 13-H, 14-H) ppm. 13C NMR
(100 MHz, CDCl3, amide conformation A): δ = 38.0 (C-7), 48.2
(C-9), 50.0 (C-4), 52.7 (C-20), 53.4 (C-10), 66.5 (C-3), 79.4 (C-8),
115.6 (C-16), 121.6 (C-18), 127.2 (C-17), 128.3 (C-13), 128.5 (C-5),
129.5 (C-12), 129.5 (C-14), 133.3 (C-6), 137.4 (C-11), 156.5 (C-15),
169.3 (C-2), 169.7 (C-19); (amide conformation B): 34.1 (C-7), 50.1
(C-10), 50.5 (C-4), 50.6 (C-9), 52.3 (C-20), 56.1 (C-3), 71.9 (C-8),
115.8 (C-16), 121.8 (C-18), 127.0 (C-17), 127.9 (C-13), 128.7 (C-
12), 128.8 (C-14), 129.4 (C-5), 131.5(C-6), 136.8 (C-11), 156.5 (C-
11), 156.7 (C-15), 169.0 (C-2), 170.0 (C-19) ppm. IR: ν = 3030,
˜
2935, 1732, 1647, 1597, 1492, 1422, 1374, 1222, 1172, 1063, 1013,
753, 695 cm–1. HRMS (ESI): calcd. for C24H26NO4ClNa [M +
Na]+ 450.1448; found 450.1450. [α]D = 19.0 (c = 1.0, CH2Cl2).
1
Data for pS-21c. Rf = 0.2 (PE/EtOAc, 5:1). H NMR (400 MHz,
3
2
CDCl3): δ = 1.34 (t, J = 7.1 Hz, 3 H, 21-H), 2.18 (td, J = 11.8,
3J = 9.2 Hz, 1 H, 7-Hβ), 3.07–3.15 (m, 1 H, 7-Hα), 3.28 (d, 2J =
14.4 Hz, 1 H, 9-Hα), 3.70–3.80 (m, 2 H, 4-H, 9-Hβ), 4.19–4.38 (m,
3 H, 10a-H, 20-H), 4.56 (dd, 3J = 16.4, 3J = 8.5 Hz, 1 H, 8-H),
15), 166.7 (C-2), 168.9 (C-19) ppm. IR: ν = 3031, 2953, 1739, 1657,
˜
1621, 1597, 1494, 1231, 1169, 1028, 913, 750, 695, 640 cm–1. HRMS
(ESI): calcd. for C23H24NO4NaCl [M + Na]+ 436.1292; found
436.1290. [α]D = –45 (c = 0.85, CH2Cl2).
3
2
4.82 (d, J = 3.6 Hz, 1 H, 3-H), 5.03 (d, J = 14.7 Hz, 1 H, 10b-
H), 5.75 (dd, 3J = 16.1, 3J = 6.2 Hz, 1 H, 5-H), 6.31 (ddd, 3J =
16.1, 3J = 12.2, 3J = 3.7 Hz, 1 H, 6-H), 6.85 (dd, 3J = 8.7, 4J =
0.9 Hz, 2 H, 16-H), 7.02–7.08 (m, 1 H, 18-H), 7.09–7.11 (m, 2 H,
13-H), 7.21–7.28 (m, 3 H, 12-H, 14-H), 7.28–7.34 (m, 2 H, 17-H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 14.4 (C-21), 39.8 (C-7), 50.5
(C-10), 51.1 (C-4), 52.4 (C-9), 57.5 (C-3), 61.5 (C-20), 75.2 (C-8),
117.3 (C-16), 122.6 (C-18), 127.7 (C-5), 128.5 (C-12), 128.6 (C-13),
128.8 (C-14), 130.0 (C-17), 132.5 (C-6), 137.1 (C-11), 157.1 (C-15),
Standard Procedure D: Same procedure as described for Standard
Procedure C, but without K2CO3.
(pS) E-3S,4S,8R-N-Benzyl-4-ethoxycarbonyl-8-(phenoxy)-3-phenyl-
2,3,4,7,8,9-hexahydro-1H-azonin-2-one (pS-14c): Reaction between
allylamine Z-6c (ethyl ester; 300 mg, 0.85 mmol) and phenylacetyl
fluoride (648 mg, 4.69 mmol) following standard procedure D. Pu-
rification by column chromatography (PE/EtOAc, 5:1) and HPLC
[Nucleosil 50–5 (ID 32ϫ250 mm), (Hex/EtOAc, 17:3), 64 mL/min,
68 bar, tR = 4.56 min] gave pS-19c (70%) as a yellow solid. Rf =
165.9 (C-2), 168.1 (C-19) ppm. IR: ν = 3029, 2930, 1736, 1650,
˜
1597, 1492, 1415, 1222, 1179, 1043, 753, 695 cm–1. HRMS (ESI):
calcd. for C24H27NO4Cl [M + H]+ 428.1629; found 428.1636. [α]D
= 107.0 (c = 0.5, CH2Cl2).
1
0.3 (PE/EtOAc, 5:1), m.p. 113 °C. H NMR (400 MHz, CDCl3): δ
3
2
3
= 1.11 (t, J = 7.1 Hz, 3 H, 21-H), 2.11 (ddd, J = 13.8, J = 11.8,
Standard Procedure E for a Transannular Ring Contraction: A solu-
tion of azoninone 8–20 (1.0 mmol) in dry CH2Cl2 (20 mL) was
treated dropwise with a solution of iodine (1.1 mmol) in dry
CH2Cl2 until the colour of unreacted iodine remained. The mixture
was stirred for a further 15 min at 23 °C to achieve complete con-
version. Then, the excess iodine was destroyed by adding saturated
aqueous Na2S2O3. The organic phase was dried (MgSO4), and con-
centrated under vacuum. The residue was purified by flash
chromatography.
3J = 5.9 Hz, 1 H, 7β-H), 2.58 (dd, J = 13.8, J = 3.4 Hz, 1 H, 7α-
2
3
H), 3.46 (dd, 2J = 14.9, 3J = 4.7 Hz, 1 H, 9β-H), 3.83 (dd, 3J =
3
3
3
10.7, J = 7.3 Hz, 1 H, 4-H), 4.13 (td, J = 7.2, J = 3.4 Hz, 2 H,
2
3
2
20-H), 4.35 (dd, J = 14.9, J = 10.0 Hz, 1 H, 9α-H), 4.52 (d, J =
14.7 Hz, 1 H, 10α-H), 4.67–4.74 (m, 1 H, 8-H) 4.71 (d, 3J =
2
10.7 Hz, 1 H, 3-H), 4.84 (d, J = 14.7 Hz, 1 H, 10β-H), 5.86 (dd,
3J = 16.4, J = 7.3 Hz, 1 H, 5-H), 6.18–6.28 (m, 1 H, 6-H), 6.75
3
3
3
(d, J = 7.8 Hz, 2 H, 23-H), 6.96 (t, J = 6.1 Hz, 1 H, 25-H), 7.19
(d, J = 2.1 Hz, 2 H, 14-H, 18-H), 7.19–7.23 (m, 2 H, 12-H), 7.21–
3
3
7.36 (m, 6 H, 13-H, 17-H, 24-H), 7.48 (d, J = 7.1 Hz, 2 H, 16-H) 2R,6R,7S,8R,8aS-6-Chloro-8-iodo-7-methoxycarbonyl-2-phenoxy-
ppm. 13C NMR (75 MHz, CDCl3): δ = 14.1 (C-21), 34.6 (C-7), 48.7 indolizidin-5-one (22c): Reaction between azoninone pS-8c
6282
www.eurjoc.org
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2014, 6272–6284